• Overall survival• Progression-free survival• Metastasis-free survival• Prostate cancer–specific survival• Time to castration resistance• Time to PSA progression• Time to first use of new antineoplastic therapy• Time to distant metastasis• Time to symptomatic progression• Time to first symptomatic skeletal event• Time to clinically relevant pain• Time to treatment discontinuation• Time to treatment resumption• Patient-reported outcomes (e.g., EORTC-QLQ-C30, FACT-P,   EQ-5D-5L, EQ-5D-3L, BPI-SF, and EORTC-QLQ-PR25)• Adverse events. This evidence concerns the gene KLK3 and Familial prostate cancer.